Abingworth as of June 30, 2017
Portfolio Holdings for Abingworth
Abingworth holds 16 positions in its portfolio as reported in the June 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Crispr Therapeutics (CRSP) | 31.0 | $39M | 2.4M | 15.94 | |
| Paratek Pharmaceuticals | 24.9 | $31M | 1.3M | 24.05 | |
| Sientra | 17.0 | $21M | 2.2M | 9.70 | |
| Cymabay Therapeutics | 7.3 | $9.2M | 1.6M | 5.76 | |
| Cascadian Therapeutics | 2.7 | $3.4M | 925k | 3.71 | |
| Immune Design | 2.7 | $3.4M | 352k | 9.65 | |
| Proteon Therapeutics | 2.4 | $3.0M | 2.0M | 1.50 | |
| Chiasma | 2.3 | $2.9M | 2.1M | 1.40 | |
| Cellectis S A (CLLS) | 2.0 | $2.6M | 100k | 25.66 | |
| Dermira | 1.6 | $2.0M | 70k | 29.11 | |
| Lombard Med (EVARF) | 1.4 | $1.8M | 3.5M | 0.52 | |
| Histogenics Corp Cmn | 1.3 | $1.6M | 889k | 1.78 | |
| Aurinia Pharmaceuticals (AUPH) | 1.2 | $1.5M | 252k | 6.12 | |
| Innocoll | 1.0 | $1.2M | 537k | 2.27 | |
| Adaptimmune Therapeutics (ADAP) | 0.9 | $1.1M | 250k | 4.50 | |
| Novan | 0.2 | $215k | 53k | 4.03 |
